Factors | Patient identification | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
Age (years) | 51 | 74 | 49 | 94 | 51 | 66 | 72 | 57 | 51 | 84 |
Sex (male/female) | M | M | F | F | F | F | M | M | M | M |
Primary disease | Follicular lymphoma | Follicular lymphoma | Myasthenia gravis | Myasthenia gravis Rheumatoid arthritis | Kidney transplant | Kidney transplant | Kidney transplant | Liver transplant | Chronic myeloid leukemia | Chronic lymphocytic leukemia |
Other comorbidity | None | Hypertension | Thyrotoxicosis | Hypertension | Epilepsy | Hypertension | Hypertension Diabetes mellitus | Hypertension Diabetes mellitus Nephrotic syndrome | None | Diabetes mellitus Coronary heart disease |
COVID-19 vaccination | Yes | Yes | No | Yes | No | Yes | Yes | Yes | No | Yes |
Anti-CD20 antibody | Obinutuzumab | Rituximab Obinutuzumab | None | None | None | None | None | None | None | None |
Immunosuppressive agents for primary disease | Cyclophosphamide Prednisolone | Cyclophosphamide Prednisolone | Tacrolimus | Tacrolimus Prednisolone | Tacrolimus Mycophenolate mofetil Everolimus Prednisolone | Tacrolimus Mycophenolate mofetil Methylprednisolone | Tacrolimus Mycophenolate mofetil Methylprednisolone | Tacrolimus Mycophenolate mofetil Everolimus | Iguratimod Tocilizumab Prednisolone | Prednisolone |
Initial antiviral therapy Switched antiviral therapy | Remdesivir | Remdesivir Nirmatrelvir/Ritonavir | Remdesivir Nirmatrelvir/Ritonavir | Remdesivir Molnupiravir | Remdesivir | Remdesivir Nirmatrelvir/Ritonavir | Remdesivir | Remdesivir Nirmatrelvir/Ritonavir | Remdesivir | Remdesivir |
Neutralizing antibody-based therapy | Sotrovimab Casirivimab/Imdevimab | Sotrovimab | Casirivimab/Imdevimab | Casirivimab/Imdevimab | Sotrovimab | Sotrovimab | Sotrovimab | Sotrovimab | Casirivimab/Imdevimab | Sotrovimab |
Initial Ct value | 18.6 | 19.8 | 25.3 | 18.2 | 19.6 | 25 | 17.9 | 22.4 | 15 | 25.6 |
Initial spike-specific antibody | Negative | Negative | 163 U/mL | Negative | Negative | Negative | Negative | Negative | Negative | 1.41 U/mL |
Length of antiviral and antibody-based therapy | 10 days | 14 days | 9 days | 10 days | 10 days | 21 days | 20 days | 18 days | 8 days | 7 days |
Length of hospital stay | 14 days | 19 days | 13 days | 28 days | 13 days | 23 days | 43 days | 18 days | 12 days | 17 days |